https://www.selleckchem.com/pr....oducts/pf-477736.htm
that Gendicine combination regimens demonstrated longer progression-free survival times than conventional treatments alone. To date, Gendicine has been clinically used in China for treatment of cancers other than HNSCC for more than ten years, mainly for patients with advanced or unresectable malignant tumors. However, the establishment of standard treatment regimens using TP53 gene therapy is still needed in order to advance its use in clinical practice. The indole framework is considered as one of the privileged structures in the ar
Like
Comment
Share
